Results 181 to 190 of about 92,178 (306)

GPCR-Mediated Signaling of Metabolites.

Cell Metabolism, 2017
A. Husted, Mette Trauelsen, O. Rudenko, S. Hjorth, T. Schwartz   +4 more
semanticscholar   +1 more source

Matsupexole: A novel nonergot dopamine receptor agonist with sustained efficacy in a rat model of Parkinson's disease and limited off‐target activity

British Journal of Pharmacology, EarlyView.
Background and Purpose Dopamine receptor agonists, particularly targeting the dopamine D2L receptor (D2LR), have been used to treat Parkinson's disease (PD). However, valvular heart disease and somnolence, mainly caused by activating the serotonin 5‐HT2B receptor (5‐HT2BR) and dopamine D3 receptor (D3R), respectively, currently challenge their clinical
Takayuki Suzuki, Fumiki Oana, Masaki Oota, Yuma Handa, Osamu Kaminuma   +4 more
wiley   +1 more source

A Transferable and Robust Computational Framework for Class A GPCR Activation Free Energies. [PDF]

J Phys Chem Lett
Aureli S, Piasentin N, Fröhlking T, Rizzi V, Gervasio FL.   +4 more
europepmc   +1 more source

Comprehensive transduceromic profiling of NOP receptor ligands at different Gα subunits

British Journal of Pharmacology, EarlyView.
Abstract Background and Purpose The nociceptin/orphanin FQ (N/OFQ) peptide receptor (NOP) is an opioid receptor family member with distinct pharmacology and broad therapeutic potential. NOP receptors regulate functions such as nociception, stress reactivity, reward, mood, autonomic tone, immunity and sleep/wake cycle.
Davide Malfacini, Riccardo Camilotto, Michele Maritan, Erika Morrone, Stephen Afriyie Boateng, Anna Vacilotto, Salvatore Pacifico, Remo Guerrini, Nurulain T. Zaveri, Girolamo Calo'   +9 more
wiley   +1 more source

Cinnamon-Derived Phytonutrients as Modulators of Ion Channels and G Protein-Coupled Receptor Signaling in Metabolic Diseases. [PDF]

Nutrients
Tjandrawinata RR, Rosari BP, Syahputra RA, Surya R, Nurkolis F.   +4 more
europepmc   +1 more source

GPCR biosensor chip [PDF]

Nature Biotechnology, 1999
openaire   +2 more sources

Second‐generation prokineticin PKR1 receptor agonists: Advancing cardioprotection against chemotherapy‐induced toxicity

British Journal of Pharmacology, EarlyView.
IS39, a novel non‐peptide PKR1 agonist, confers cardioprotection against doxorubicin‐induced toxicity. IS39 activates PKR1‐mediated pro‐survival signalling in cardiomyocytes, reducing reactive oxygen species (ROS), DNA damage and fibrosis markers. In vivo, IS39 preserves cardiac geometry and function in mice exposed to chronic doxorubicin challenge ...
Anais Audebrand, Simone Brogi, Mustafa Tezeren, Andrea Tafi, Omer H. Ocak, Hasan Koyuncu, Igor Tetko, Laurent Désaubry, Canan G. Nebigil   +8 more
wiley   +1 more source

Re-evaluating Gα protein-response element specificity in GPCR signaling. [PDF]

Commun Biol
Saito A, Kise R, Yamaguchi S, Yanagawa M, Inoue A.   +4 more
europepmc   +1 more source

Strategic advances for cryo-EM structural studies of small (<100 kDa) GPCRs. [PDF]

Commun Biol
Singh SK, Agrawal M, Pattanayak A, Baidya M, Kumari P.   +4 more
europepmc   +1 more source

Distinct conformations of GPCR–β-arrestin complexes mediate desensitization, signaling, and endocytosis

Proceedings of the National Academy of Sciences of the United States of America, 2017
T. Cahill, A. Thomsen, Jeffrey Tarrasch, Bianca Plouffe, Anthony H. Nguyen, Fan Yang, Li-Yin Huang, Alem W. Kahsai, D. Bassoni, Bryant J. Gavino, J. Lamerdin, Sarah Triest, A. Shukla, B. Berger, John Little, A. Antar, Adi Blanc, C. Qu, Xin Chen, Kouki Kawakami, A. Inoue, J. Aoki, J. Steyaert, Jin-peng Sun, M. Bouvier, G. Skiniotis, R. Lefkowitz   +26 more
semanticscholar   +1 more source